tiprankstipranks
Trending News
More News >
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
US Market

Aclaris Therapeutics (ACRS) Stock Forecast & Price Target

Compare
746 Followers
See the Price Targets and Ratings of:

ACRS Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Aclaris
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACRS Stock 12 Month Forecast

Average Price Target

$9.75
▲(537.25%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is $9.75 with a high forecast of $16.00 and a low forecast of $7.00. The average price target represents a 537.25% change from the last price of $1.53.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Sep<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,2.5046153846153847,3.6292307692307695,4.753846153846155,5.878461538461539,7.003076923076924,8.127692307692309,9.252307692307692,10.376923076923077,11.501538461538463,12.626153846153848,13.750769230769233,14.875384615384618,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,2.023846153846154,2.667692307692308,3.3115384615384618,3.9553846153846157,4.59923076923077,5.243076923076924,5.886923076923078,6.5307692307692315,7.174615384615385,7.8184615384615395,8.462307692307693,9.106153846153848,{"y":9.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,1.8123076923076922,2.2446153846153845,2.676923076923077,3.109230769230769,3.5415384615384617,3.973846153846154,4.406153846153846,4.838461538461539,5.270769230769231,5.703076923076924,6.135384615384615,6.567692307692308,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.05,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16.00Average Price Target$9.75Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on ACRS
Thomas SmithLeerink Partners
Leerink Partners
$7
Buy
357.52%
Upside
Reiterated
05/28/25
Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments
H.C. Wainwright Analyst forecast on ACRS
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$20$16
Buy
945.75%
Upside
Reiterated
05/14/25
Aclaris Therapeutics price target lowered to $16 from $20 at H.C. WainwrightAclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
Scotiabank Analyst forecast on ACRS
Louise ChenScotiabank
Scotiabank
$15$9
Buy
488.24%
Upside
Reiterated
05/09/25
Aclaris Therapeutics price target lowered to $9 from $15 at ScotiabankAclaris Therapeutics price target lowered to $9 from $15 at Scotiabank
Jefferies Analyst forecast on ACRS
Roger SongJefferies
Jefferies
$7
Buy
357.52%
Upside
Reiterated
04/24/25
Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
Cantor Fitzgerald Analyst forecast on ACRS
Prakhar AgrawalCantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
03/18/25
Aclaris Therapeutics assumed with an Overweight at Cantor FitzgeraldAclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald
Stifel Nicolaus Analyst forecast on ACRS
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$5$2
Hold
30.72%
Upside
Reiterated
03/03/25
Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)
Piper Sandler Analyst forecast on ACRS
Christopher RaymondPiper Sandler
Piper Sandler
$13
Buy
749.67%
Upside
Reiterated
02/18/25
Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)
BTIG
$8
Buy
422.88%
Upside
Upgraded
11/18/24
Aclaris Therapeutics: Promising Pipeline Developments and Strategic Acquisitions Bolster Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on ACRS
Thomas SmithLeerink Partners
Leerink Partners
$7
Buy
357.52%
Upside
Reiterated
05/28/25
Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments
H.C. Wainwright Analyst forecast on ACRS
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$20$16
Buy
945.75%
Upside
Reiterated
05/14/25
Aclaris Therapeutics price target lowered to $16 from $20 at H.C. WainwrightAclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
Scotiabank Analyst forecast on ACRS
Louise ChenScotiabank
Scotiabank
$15$9
Buy
488.24%
Upside
Reiterated
05/09/25
Aclaris Therapeutics price target lowered to $9 from $15 at ScotiabankAclaris Therapeutics price target lowered to $9 from $15 at Scotiabank
Jefferies Analyst forecast on ACRS
Roger SongJefferies
Jefferies
$7
Buy
357.52%
Upside
Reiterated
04/24/25
Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
Cantor Fitzgerald Analyst forecast on ACRS
Prakhar AgrawalCantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
03/18/25
Aclaris Therapeutics assumed with an Overweight at Cantor FitzgeraldAclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald
Stifel Nicolaus Analyst forecast on ACRS
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$5$2
Hold
30.72%
Upside
Reiterated
03/03/25
Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)
Piper Sandler Analyst forecast on ACRS
Christopher RaymondPiper Sandler
Piper Sandler
$13
Buy
749.67%
Upside
Reiterated
02/18/25
Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)
BTIG
$8
Buy
422.88%
Upside
Upgraded
11/18/24
Aclaris Therapeutics: Promising Pipeline Developments and Strategic Acquisitions Bolster Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aclaris Therapeutics

1 Month
xxx
Success Rate
7/13 ratings generated profit
54%
Average Return
-3.13%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of -3.13% per trade.
3 Months
xxx
Success Rate
5/13 ratings generated profit
38%
Average Return
-17.90%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of -17.90% per trade.
1 Year
Roger SongJefferies
Success Rate
3/12 ratings generated profit
25%
Average Return
-31.95%
reiterated a buy rating last month
Copying Roger Song's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -31.95% per trade.
2 Years
xxx
Success Rate
6/14 ratings generated profit
43%
Average Return
+108.32%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of +108.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACRS Analyst Recommendation Trends

Rating
Dec 24
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
6
8
5
4
6
Buy
1
1
1
1
1
Hold
6
4
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
13
8
6
8
In the current month, ACRS has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ACRS average Analyst price target in the past 3 months is 9.75.
Each month's total comprises the sum of three months' worth of ratings.

ACRS Financial Forecast

ACRS Earnings Forecast

Next quarter’s earnings estimate for ACRS is -$0.14 with a range of -$0.16 to -$0.12. The previous quarter’s EPS was -$0.12. ACRS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ACRS has Outperformed its overall industry.
Next quarter’s earnings estimate for ACRS is -$0.14 with a range of -$0.16 to -$0.12. The previous quarter’s EPS was -$0.12. ACRS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ACRS has Outperformed its overall industry.

ACRS Sales Forecast

Next quarter’s sales forecast for ACRS is $1.32M with a range of $300.00K to $2.70M. The previous quarter’s sales results were $1.46M. ACRS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year ACRS has Outperformed its overall industry.
Next quarter’s sales forecast for ACRS is $1.32M with a range of $300.00K to $2.70M. The previous quarter’s sales results were $1.46M. ACRS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year ACRS has Outperformed its overall industry.

ACRS Stock Forecast FAQ

What is ACRS’s average 12-month price target, according to analysts?
Based on analyst ratings, Aclaris Therapeutics’s 12-month average price target is 9.75.
    What is ACRS’s upside potential, based on the analysts’ average price target?
    Aclaris Therapeutics has 537.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACRS a Buy, Sell or Hold?
          Aclaris Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Aclaris Therapeutics’s price target?
            The average price target for Aclaris Therapeutics is 9.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $16.00 ,the lowest forecast is $7.00. The average price target represents 537.25% Increase from the current price of $1.53.
              What do analysts say about Aclaris Therapeutics?
              Aclaris Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of ACRS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis